NCT01776879 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Amir, O
, Ashkenazi, O., Leibovitzh, T., Michael, O., Tavor, Y., & Wolf, M. (2006). Applying the Voice Handicap Index (VHI) to Dysphonic and Nondysphonic Hebrew Speakers. Journal of Voice, 318-324. Giladi, N., Treves, T. A., Paleacu, D., Shabtai, H., Orlov, Y., Kandinov, B., Simon, E. S., & Korczyn, A. D. (2000). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695-699 Sapir, S., Raming, L., & Fox, C. (2008) speech and swallowing disorder In Parkinson disease. Speech therapy and rehabilitation. 205-210. Wolters, E. Ch. (2009). Non-motor extranigral signs and symptoms in Parkinson's disease. Parkinsonism and Related Disorders , 6-12. Manor, Y. Giladi, N. Cohen, A. Fliss, D. Cohen. Y. (2007) Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson's disease. Movement Disorders.

Speech Intelligibility of Patients With Parkinsons Disease at Different Stages of the Disease Compared to First Degree Relatives of Parkinson's Disease Patients

Details for clinical trial NCT01776879

Clinical trial NCT01776879 - References